Correction: STOCKWATCH: Vertex's almost incomplete disclosure
This article was originally published in Scrip
Executive Summary
In the previous version of this article it was not stated that the full data set of Vertex's 194 patient clinical study had been reported. This was incorrect as the full data set was released by the company and discussed in a conference call on April 18. That press release included a table showing changes relative to placebo, for the secondary endpoint of FEV1 showing that only the top two doses were significantly different from placebo and the highest doses had a lower efficacy than the second highest doses.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.